Dr. Goodman is a highly experienced health economics and market access leader with more than 20 years of experience spanning global pricing and reimbursement strategy, real-world evidence generation, and value-based healthcare modeling across the biotechnology, pharmaceutical, diagnostics, and medical device sectors. He has led the development of payer engagement strategies, health technology assessment (HTA) dossiers, and value frameworks supporting product launches and commercialization for leading healthcare organizations.
Dr. Goodman has advised leading global healthcare organizations, including Pfizer, Gilead Sciences, and Moderna, and has worked closely with government agencies such as the Centers for Medicare & Medicaid Services on value-based pricing and reimbursement frameworks. He has also served as a healthcare policy advisor to the White House on multiple health reform initiatives, contributing to the development of reimbursement and access frameworks at both the federal and state levels.
Dr. Goodman holds a Ph.D. and Master of Healthcare Administration from the Harvard T.H. Chan School of Public Health and a Bachelor of Arts in Medical Communications from North Texas State University.